Novavax Inc. stock underperforms Wednesday when compared to competitors | news.google.com • |
Shah Capital Management Acquires 1,544,263 Shares of Novavax, Inc. (NASDAQ:NVAX) | news.google.com • |
Novavax Inc. stock underperforms Tuesday when compared to competitors | news.google.com • |
Novavax Inc. stock underperforms Tuesday when compared to competitors | news.google.com • |
Novavax Inc. stock underperforms Tuesday when compared to competitors | news.google.com • |
Why Novavax is Gaining Ground in COVID-19 Vaccine Race | zacks.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-08-08 | 2024-06 | 1.82 | 0.99 | -0.83 | -45.60% |
2024-05-10 | 2024-03 | -1.04 | -1.05 | -0.01 | -0.96% |
2024-02-28 | 2023-12 | -0.49 | -1.44 | -0.95 | -193.88% |
2023-11-09 | 2023-09 | -1.82 | -1.26 | 0.56 | 30.77% |
2023-08-08 | 2023-06 | -1.24 | 0.58 | 1.82 | 146.77% |
2023-05-09 | 2023-03 | -3.38 | -3.41 | -0.03 | -0.89% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-08-09 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-08-08 | B. Riley Securities | Upgrade | Neutral | Buy |
2023-05-09 | HC Wainwright & Co. | Upgrade | Buy | |
2023-02-28 | B. Riley Securities | Downgrade | Buy | Neutral |
2023-02-12 | HC Wainwright & Co. | Upgrade | Buy | |
2023-01-01 | HC Wainwright & Co. | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-06-11 | ALTON GREGG H | Director | 10.47K | Conversion of Exercise of derivative security |
2024-06-11 | DOUGLAS RICHARD H | Director | 43.92K | Conversion of Exercise of derivative security |
2024-06-16 | DUBOVSKY FILIP | Officer | 66.61K | Sale |
2024-08-15 | KELLY JAMES PATRICK | Chief Financial Officer | 14.43K | Conversion of Exercise of derivative security |
2024-06-11 | KING RACHEL K | Director | 18.92K | Conversion of Exercise of derivative security |
2024-06-11 | MCGLYNN MARGARET G | Director | 10.47K | Conversion of Exercise of derivative security |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | State Street Corporation | 11.68M | 86.78M | 12.37% |
2023-06-29 | Vanguard Group Inc | 10.57M | 78.55M | 11.20% |
2023-06-29 | Blackrock Inc. | 6.99M | 51.97M | 7.41% |
2023-09-29 | Shah Capital Management | 6.33M | 45.83M | 6.71% |
2023-06-29 | Bank of America Corporation | 2.18M | 16.23M | 2.31% |
2023-06-29 | Morgan Stanley | 2.08M | 15.46M | 2.20% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-08-30 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 9.38M | 75.07M | 9.94% |
2023-06-29 | Vanguard Total Stock Market Index Fund | 2.64M | 19.60M | 2.79% |
2023-06-29 | Vanguard Small-Cap Index Fund | 2.23M | 16.56M | 2.36% |
2023-08-30 | iShares Russell 2000 ETF | 2.01M | 16.10M | 2.13% |
2023-06-29 | Vanguard Small-Cap Growth Index Fund | 1.28M | 9.48M | 1.35% |
2023-06-29 | Vanguard Extended Market Index Fund | 1.21M | 8.98M | 1.28% |
Split | Date |
---|---|
1 : 20 | 2019-05-10 |
-
September 12, 2023
Today the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted in favor (13 in favor and 1 against) of a universal recommendation for the use of 2023-2024 (monovalent, XBB containing) COVID-19 vaccines authorized under Emergency Use Authorization (EUA) or approved by Biologics License Application. This vote was later endorsed by the CDC.
“Novavax is pleased that discussions at today’s ACIP meeting showed broad support for COVID vaccination this season via a universal recommendation, and also highlighted the urgent need for a protein-based option. Based on today’s discussion and upon authorization from the FDA, we anticipate that Novavax’s XBB COVID vaccine will be included in the ACIP’s recommendations in accordance with our label,” said John C. Jacobs, President and Chief Executive Officer, Novavax. “Doses of Novavax’s vaccine are already in the U.S. and once authorized, will be the only protein-based non-mRNA vaccine option available for individuals aged 12 and older.”
Novavax presented non-clinical data at the ACIP meeting showing that Novavax’s COVID-19 Vaccine, Adjuvanted (Formula 2023-2024) induced neutralizing antibody responses to a broad range of circulating variants including new data on the FL.1.5.1 (“Fornax”) subvariant as well as robust CD4+ polyfunctional cellular (T-cell) responses against EG.5.1 and XBB.1.16.6, which are becoming more prevalent in the U.S. These data indicate the vaccine can stimulate both arms of the immune system and is capable of inducing a broad response against circulating variants.2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Novavax Inc. stock underperforms Wednesday when compared to competitors
news.google.com • -
Novavax Inc. stock underperforms Tuesday when compared to competitors
news.google.com • -
Novavax Inc. stock underperforms Tuesday when compared to competitors
news.google.com • -
Novavax Inc. stock underperforms Tuesday when compared to competitors
news.google.com • -
Why Novavax is Gaining Ground in COVID-19 Vaccine Race
news.google.com • -
Novavax Inc. stock underperforms Monday when compared to competitors
news.google.com • -
Novavax Inc. stock underperforms Monday when compared to competitors
news.google.com • -
Novavax Inc. stock underperforms Monday when compared to competitors
news.google.com • -
(NVAX) Trading Report
news.google.com • -
Novavax Inc. stock outperforms competitors on strong trading day
news.google.com • -
Should You Buy Novavax Stock After This Regulatory Win?
news.google.com • -
Should You Buy Novavax Stock After This Regulatory Win?
news.google.com • -
Novavax Inc. stock underperforms Thursday when compared to competitors
news.google.com • -
Why Are Novavax Shares Trading Lower Today?
news.google.com • -
Novavax Inc. stock underperforms Wednesday when compared to competitors
news.google.com • -
Novavax, Inc. (NVAX) Baird 2024 Global Healthcare Conference (Transcript)
seekingalpha.com • -
Novavax to Participate in Upcoming September Conferences
prnewswire.com • -
Novavax: Staying Long Despite Coming Up Short In Q2
seekingalpha.com • -
Novavax Plunges on Earnings Miss: Falling Knife or Buying Opp?
marketbeat.com • -
Novavax, Inc. (NVAX) Q2 2024 Earnings Call Transcript
seekingalpha.com •